Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load

Microglia, the primary immune cells of the brain, play a key role in pathological and normal brain function. Growing efforts aim to reveal how these cells may be harnessed to treat both neurodegenerative diseases such as Alzheimer’s and developmental disorders such as schizophrenia and autism. We recently showed that using noninvasive exposure to 40-Hz white-light (4,000 K) flicker to drive 40-Hz neural activity transforms microglia into an engulfing state and reduces amyloid beta, a peptide thought to initiate neurotoxic events in Alzheimer’s disease (AD). This article describes how to construct an LED-based light-flicker apparatus, expose animals to 40-Hz flicker and control conditions, and perform downstream assays to study the effects of these stimuli. Light flicker is simple, faster to implement, and noninvasive, as compared with driving 40-Hz activity using optogenetics; however, it does not target specific cell types, as is achievable with optogenetics. This noninvasive approach to driving 40-Hz neural activity should enable further research into the interactions between neural activity, molecular pathology, and the brain’s immune system. Construction of the light-flicker system requires ~1 d and some electronics experience or available guidance. The flicker manipulation and assessment can be completed in a few days, depending on the experimental design.This protocol describes a noninvasive approach to evoke microglial engulfment and reduce amyloid levels in mouse brain. The authors describe assembly and operation of a light-flicker system, as well as assessment of the molecular and cellular effects.

[1]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[2]  M. Murphy,et al.  Alzheimer's disease and the amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[3]  Jessica A. Cardin,et al.  Driving fast-spiking cells induces gamma rhythm and controls sensory responses , 2009, Nature.

[4]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[5]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[6]  K. Deisseroth,et al.  Advanced CLARITY for rapid and high-resolution imaging of intact tissues , 2014, Nature Protocols.

[7]  Aaron S. Andalman,et al.  Structural and molecular interrogation of intact biological systems , 2013, Nature.

[8]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[9]  Kwanghun Chung,et al.  Simple, Scalable Proteomic Imaging for High-Dimensional Profiling of Intact Systems , 2015, Cell.

[10]  Edward S Boyden,et al.  Principles of designing interpretable optogenetic behavior experiments , 2015, Learning & memory.

[11]  Georg W. Kreutzberg,et al.  Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function , 1999, Brain Research Reviews.

[12]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[14]  R. Eckhorn,et al.  Coherent oscillations: A mechanism of feature linking in the visual cortex? , 1988, Biological Cybernetics.

[15]  Heng Du,et al.  Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer’s disease , 2016, Nature Communications.

[16]  H. Kettenmann,et al.  Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.

[17]  B. MacVicar,et al.  Microglia: Dynamic Mediators of Synapse Development and Plasticity. , 2015, Trends in immunology.

[18]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[19]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[20]  G. Kreutzberg.  Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[21]  Yixin Chen,et al.  Square or Sine: Finding a Waveform with High Success Rate of Eliciting SSVEP , 2011, Comput. Intell. Neurosci..

[22]  A. Cardona,et al.  Isolation and Analysis of Mouse Microglial Cells , 2014, Current protocols in immunology.

[23]  E. Boyden,et al.  Gamma frequency entrainment attenuates amyloid load and modifies microglia , 2016, Nature.

[24]  E. Neufeld,et al.  Defects in the Medial Entorhinal Cortex and Dentate Gyrus in the Mouse Model of Sanfilippo Syndrome Type B , 2011, PloS one.

[25]  I. Lindberg,et al.  The Neuroendocrine Protein 7B2 Suppresses the Aggregation of Neurodegenerative Disease-related Proteins , 2012, The Journal of Biological Chemistry.

[26]  L. Alberi,et al.  Notch1 hallmarks fibrillary depositions in sporadic Alzheimer’s disease , 2016, Acta Neuropathologica Communications.

[27]  A. Bessis,et al.  Microglial control of neuronal death and synaptic properties , 2007, Glia.

[28]  W. Bowers,et al.  Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice , 2008, BMC Neuroscience.

[29]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[30]  D. Holtzman,et al.  TREM2 lipid sensing sustains microglia response in an Alzheimer’s disease model , 2015, Cell.

[31]  P. Treuting,et al.  Mouse Necropsy , 2015, Current protocols in mouse biology.

[32]  T. Golde,et al.  Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease. , 2009, Molecular Therapy.

[33]  K. Deisseroth,et al.  CLARITY for mapping the nervous system , 2013, Nature Methods.

[34]  Ana L. N. Fred,et al.  Unveiling the Biometric Potential of Finger-Based ECG Signals , 2011, Comput. Intell. Neurosci..

[35]  T. Golde,et al.  Generating Differentially Targeted Amyloid-β Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Manolis Kellis,et al.  Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease , 2015, Nature.

[37]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[38]  R. Ransohoff.  A polarizing question: do M1 and M2 microglia exist? , 2016, Nature Neuroscience.